Table 2. Updated survival analysis of all patients in the MORE study, stratified by baseline characteristics*.

Characteristic	N	Survival, months		P-values between subgroups, P-value (log-rank)
		Median	95% CI
All	606	10.0	9.2–11.8
Sex				0.59
Female	233	9.5	8.9–12.1
Male	373	10.4	9.1–12.2
Age				0.26
<70 years	446	10.4	9.2–12.0
≥70 years	160	9.4	8.0–12.1
ECOG performance status				0.004
0	168	11.2	9.2–13.1
1	72	8.5	6.5–12.8
2	14	5.5	2.3–12.2
3	3	5.0	1.3–11.0
Ascites				<0.001
No	563	10.8	9.3–12.1
Yes (controlled)	5	2.4	0.7–22.9
Yes (uncontrolled)	23	5.5	3.8–7.4
Extra-hepatic metastases				<0.001
No	393	12.3	11.2–13.9
Yes	213	7.7	6.4–8.7
In-situ primary				0.01
No	522	10.5	9.2–12.1
Yes	78	8.2	6.3–12.0
Metastases				0.015
Metachronous	173	11.3	9.2–13.9
Synchronous	396	9.4	8.7–11.1
Tumor-to-target liver involvement				<0.001
<25%	388	13.1	11.6–14.0
25-50%	148	6.7	5.9–8.2
>50%	22	6.5	3.6–11.0
Prior lines of chemotherapy				<0.001
0 (RE 1st line)	35	15.6	9.3–21.4
1 (RE 2nd-line)	206	13.2	10.9–15.5
2 (RE 3rd-line)	184	9.1	7.8–11.2
3+ (RE 4th+ line)	158	8.1	6.4–9.3
Lung shunt				<0.001
≤10%	526	10.8	9.4–12.2
>10%	70	6.8	5.2–9.0
Albumin, CTC grade				<0.001
0	392	13.1	12.1–14.4
≥1	199	6.4	5.4–7.1
Alkaline phosphatase, CTC grade				<0.001
0	241	16.3	14.4–18.3
≥1	351	7.2	6.5–8.2
Aspartate aminotransferase, CTC grade				<0.001
0	296	14.6	13.0–15.9
≥1	294	7.4	6.4–8.7
Carcinoembryonic antigen				<0.001
<median (62.2)	215	15.6	13.1–17.7
≥median (62.2)	215	7.4	6.6–8.5
Hemoglobin, CTC grade				<0.001
0	356	12.3	10.8–14.0
≥1	238	8.1	6.5–9.3
Total bilirubin, CTC grade				0.013
0	556	10.8	9.4–12.1
≥1	37	3.8	2.7–8.5

*, P-value by ANOVA for continuous variables, etc., as described in Methods.